News from csl behring A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jul 01, 2019, 18:15 ET CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019

Global biotherapeutics leader CSL Behring announced today that the company will support the presentation of new data from its recombinant coagulation ...


Jun 20, 2019, 07:00 ET CSL Behring to showcase clinical advances and insights in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with Hizentra ® [human normal immunoglobulin, 20%, subcutaneous], at the 2019 Peripheral Nerve Society Annual Meeting

Global biotherapeutics leader CSL Behring today announced that it will support the presentation of eight scientific posters at the 2019 annual...


May 16, 2019, 03:15 ET Top Coagulation Researchers Awarded Grants to Support Advancements in the Care of Patients with Bleeding Disorders

Global biotherapeutics leader CSL Behring today announced that the company has named five recipients of the 2019 Professor Heimburger Award for...


Apr 25, 2019, 08:37 ET CSL Behring Delivers on its Continued Commitment to Alpha 1 Patients with FDA Approval of Convenient Single-Vial Dosing for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)]

Global biotherapeutics leader CSL Behring today announced that the US Food and Drug Administration (FDA) has approved 4- and 5-gram vial sizes for...


Mar 26, 2019, 12:21 ET Japan's Ministry of Health, Labour and Welfare Approves CSL Behring Immunoglobulins to Treat Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Global biotherapeutics leader CSL Behring announced today that Japan's Ministry of Health, Labour and Welfare has approved two of its immunoglobulin...


Feb 04, 2019, 09:33 ET CSL Behring Extends Support of World Federation of Hemophilia Programs

The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring today announced that the company has renewed its commitment as ...


Jan 16, 2019, 09:50 ET CSL Named One of the Best Employers in the US for Diversity

Forbes magazine has named global biotechnology leader CSL Limited as one of The Best Employers for Diversity in the United States. CSL, the fifth...


Jan 07, 2019, 08:30 ET Global Biotech Leader CSL to Present at J.P. Morgan Healthcare Conference on Wednesday, January 9

Global biotechnology giant CSL Limited, parent company of biotherapeutics leader CSL Behring and world-leading influenza provider Seqirus, today...


Dec 06, 2018, 09:10 ET CSL CEO Paul Perreault Earns 2018 Most Admired CEOs Recognition from the Philadelphia Business Journal

Paul Perreault, CEO and Managing Director of CSL Limited, is one of the Philadelphia Business Journal's Most Admired CEOs for 2018, recognizing his...


Oct 22, 2018, 04:40 ET CSL Behring to Feature Secondary Immunodeficiency Symposium at the 2018 Meeting of the European Society for Immunodeficiencies (ESID)

Global biotherapeutics leader CSL Behring today announced that it will host a panel of cross-specialty experts at its "Current and Emerging Causes of ...


Sep 18, 2018, 09:45 ET CSL Named One of the Top Companies in the World for Diversity and Inclusion

Thomson Reuters has ranked global biotechnology leader CSL Limited one of the top 100 companies in its 2018 global Diversity and Inclusion Index....


Sep 13, 2018, 03:45 ET CSL Behring Delivers on its Promise to Support Alpha 1 Patients at the 28th Annual European Respiratory Society Congress

Global biotherapeutics leader CSL Behring will host a symposium about Alpha 1 Antitrypsin Deficiency (AATD) on Monday, 17 September, during the 28th...


Aug 23, 2018, 09:00 ET IDELVION® 3500 IU Vials Now Available to Provide Convenience to Patients

Global biotherapeutics leader CSL Behring today announced that IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rFIX-FP)], its ...


Jul 20, 2018, 09:00 ET CSL Behring Hosts Symposium on Managing CIDP with Immunoglobulin, Supports 14 Scientific Posters and Two Oral Presentations at the 2018 Peripheral Nerve Society Annual Meeting

Global biotherapeutics leader CSL Behring today announced that it will support the presentation of 14 scientific posters at the 2018 annual meeting...


Jul 05, 2018, 03:00 ET CSL Behring, Leader in Rare Diseases, Hosts a Symposium on CIDP, Presents 7 Poster Sessions Featuring PATH Study Data at the 15th International Congress on Neuromuscular Diseases (ICNMD)

Global biotherapeutics leader CSL Behring today announced that it will participate in the 15th International Congress on Neuromuscular Diseases...


Jun 22, 2018, 11:59 ET A New Generation Of Coagulation Specialists Is Advancing Research With Support From CSL Behring Global Grant

An exciting cross-section of coagulation research is being presented today by the recipients of CSL Behring's 2018 Prof. Heimburger Award at the...


May 31, 2018, 09:00 ET IDELVION® Newly Approved 3500 IU Vial to Provide Convenience to Patients Using Larger Volumes

Global biotherapeutics leader CSL Behring today announced that the US Food and Drug Administration (FDA) has approved a 3500 IU (international unit)...


May 14, 2018, 03:00 ET Hemophilia Association Of New Jersey Recognizes CSL CEO Paul Perreault As "Humanitarian Man Of The Year"

CEO and Managing Director of CSL Limited Paul Perreault has been named "Humanitarian Man of the Year" by the Hemophilia Association of New Jersey...


Apr 26, 2018, 09:00 ET Patient Advocacy Groups Focus On Key Issues Affecting Patients

Patient advocacy groups in Michigan, Washington, Illinois, Missouri and South Carolina are preparing to meet the many challenges standing between...


Apr 20, 2018, 08:30 ET CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting

Global biotherapeutics leader CSL Behring today announced that it will host an Industry Therapeutic Update at the 2018 annual meeting of the American ...


Apr 12, 2018, 10:15 ET Life-Saving Medicines Donated For Patients In The Developing World

The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring announced today that CSL Behring has shipped more than 10...


Mar 23, 2018, 09:55 ET CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors

CSL Behring, a global biotherapeutics leader, today announced the initiation of the AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes II)...


Mar 16, 2018, 08:00 ET FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) approved Hizentra® (Immune Globulin...


Mar 15, 2018, 09:00 ET CSL Behring Receives Patient Impact Award For Subcutaneous Prophylactic Treatment To Prevent Hereditary Angioedema Attacks

Imagine not knowing when you might experience unpredictable, severe and painful swelling without warning in different parts of your body, including...


Mar 13, 2018, 12:19 ET CSL CEO Paul Perreault Calls on Industry to Improve Patients' Access to Medicines

In a keynote address on patients' access to medicines at the eyeforpharma Barcelona summit, CSL Chief Executive Officer and Managing Director Paul...